Last10K.com

Blonder Tongue Laboratories Inc (BDR) SEC Filing 10-Q Quarterly Report for the period ending Wednesday, June 30, 2021

Blonder Tongue Laboratories Inc

CIK: 1000683 Ticker: BDR

Exhibit 99.1

 

 

 

FOR IMMEDIATE RELEASE:

 

Blonder Tongue Announces Second Quarter and Six Months 2021 Results

 

OLD BRIDGE, NJ / August 12, 2021 / Blonder Tongue Laboratories, Inc. (NYSE American: BDR) announced its sales and results for the second quarter and six months ended June 30, 2021.

 

Blonder Tongue Laboratories, Inc. net sales increased $507,000 or 13.2% to $4,338,000 for the second quarter of 2021 from $3,831,000 for the comparable period in 2020. Net income for the three months ended June 30, 2021, was $1,626,000 or $0.11 per diluted share, compared to a net loss of $(1,194,000) or $(0.12) per diluted share for the comparable period in 2020.

 

Commenting on the second quarter results, Ted Grauch, Blonder Tongue Laboratories’ President and CEO noted, “In Q2 the Company saw several elements of our long-term strategy begin to come together yielding a positive first half in terms of income and net cash provided by operating activities. Our continued multi-year R&D investment in cutting edge digital IP and OTT video products led to significant year on year growth in our Clearview transcoder and NXG IP video processing product lines, helped by new customer wins by both product lines this year. Our expanded network of channel partners and direct service operator customers resulted in broader sources of revenue over the first half that we expect will continue for the foreseeable future. Also helping us along has been a continued steady improvement in the telecommunications and video service provider technology marketplace during the first half compared with the first 9 months of the pandemic in 2020. Our CPE programs are showing a planned reduction in revenue, as we transform those products and associated customer base into a service and fulfillment model. We will be transitioning a majority of future CPE COGS onto our product partners with a goal of greatly increasing the margins and cash-efficiency of those products going forward. Although the hospitality industry has been improving the last few months, it has lagged the recovery of the telecommunications sectors and so we will be working to improve our DOCSIS product line performance in the second half of the year to the extent allowed by hospitality market capital investment improvements. Finally, we are already working hard in the second half with a goal to keep up the momentum created in first half of 2021; expanding our broadband, ISP data delivery and ATSC off-air video related product lines, as well as bringing new technology to modernize a selection of Blonder Tongue headend and central office distribution products, already well-known for decades-long reliability in the field.”

 

The increase in sales for the second quarter is primarily attributable to an increase in sales of video transcoder products, NXG IP video signal processing products and digital video headend products, offset by a decrease in sales of DOCSIS data products and CPE products. Sales of transcoder products were $1,337,000 and $279,000, NXG products were $470,000 and $285,000, digital video headend products were $968,000 and $745,000, DOCSIS data products were $327,000 and $701,000, and CPE products were $288,000 and $1,026,000 in the second three months of 2021 and 2020, respectively.

 

More…

 

   

 

 

For the six months ended June 30, 2021, net sales decreased $292,000 or 3.7% to $7,589,000 in 2021 from $7,881,000 for the comparable period in 2020. Net income for the six months ended June 30, 2021, was $1,212,000 or $0.08 per diluted share, compared to a net loss of $(3,274,000) or $(0.34) per diluted share for the comparable period in 2020. Net cash provided by operating activities was $126,000 for the first six months of 2021, compared to net cash used in operating activities of $(2,029,000) for the comparable period of 2020.

 

The decrease in sales for the six months is primarily attributable to a decrease in sales of DOCSIS data products, digital video headend products, HFC distribution products and CPE products, offset by an increase in sales of transcoder products and NXG products. Sales of DOCSIS data products were $355,000 and $1,572,000, digital video headend products were $1,511,000 and $1,802,000, HFC distribution products were $923,000 and $1,170,000, CPE products were $983,000 and $1,672,000, transcoder products were $2,073,000 and $394,000 and NXG products were $891,000 and $481,000 in the first six months of 2021 and 2020, respectively.

 

The Company expects bookings of transcoder products to remain healthy as market exposure to, and acceptance of those products continues. The Company expects sales of CPE products to continue to trend lower than in prior periods as the Company, consistent with its business plan, transitions those products into a higher margin but lower revenue services, fulfillment, and support business model, and works to promote an expanded array of distribution, content delivery and processing technologies to those service provider customers.

 

The Company’s primary sources of liquidity have been its existing cash balances, cash generated from operations and amounts available under the MidCap Facility. At June 30, 2021, the Company had $487,000 available under the MidCap Facility.

 

As disclosed in the Company’s 2020 Annual Report on Form 10-K, last year the Company experienced a decline in sales, a reduction in working capital, a loss from operations and net cash used in operating activities, in conjunction with liquidity constraints. These factors raised substantial doubt about the Company’s ability to continue as a going concern. The above factors still exist. Accordingly, there still exists substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Conference Call Reminder

 

Details of the live teleconference:

 

Date: Thursday, August 12, 2021

Time: 11:00 a.m. Eastern Time (10:00 a.m. CT, 8:00 a.m. PT)

Investor Dial-in (US & Canada Toll-Free):  888-506-0062

International: 973-528-0011

Entry Code: 705019

 

 

© Blonder Tongue Laboratories, Inc. | One Jake Brown Road, Old Bridge, NJ 08857 | (800) 523-6049 | Fax: (732) 679-4353 | www.blondertongue.com

 

 2 

 

 

 

 

The audio replay will be available under Investor Related Information on the Blonder Tongue Investor Relations webpage.

 

About Blonder Tongue

 

Blonder Tongue Laboratories, Inc. is the oldest designer and manufacturer of telecommunications and cable television video transmission technology in the USA. The majority of our products continue to be designed and built in our state-of-the-art New Jersey facility, which has been the Company’s home for more than 50 years. Blonder Tongue Labs offers U.S.-based engineering and manufacturing excellence with an industry reputation for delivering ultra-high reliability products. As a leader in cable television system design, the Company provides service operators and systems integrators with comprehensive solutions for the management and distribution of digital video, IPTV and high-speed data services, as well as RF broadband distribution over fiber, IP, and Coax networks for homes and businesses. Additional information on the Company and its products can be found at www.blondertongue.com.

 

Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The information set forth above includes “forward-looking” statements. The forward-looking statements relate to future events regarding such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. In order to comply with the terms of the safe harbor provisions, the Company notes that a variety of factors could cause our actual results and experience to differ materially and adversely from the anticipated results or other expectations expressed in the forward-looking statements. The risks and uncertainties that may affect the operation, performance, development and results of the Company’s business include, but are not limited to, those matters discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 in the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors,” and in the same sections of the Company’s subsequently-filed Quarterly Reports on Form 10-Q, as may be further updated by any Current Reports on Form 8-K that we may file. The words “believe,” “expect,” “anticipate,” “project,” “target,” “intend,” “plan,” “seek,” “estimate,” “endeavor,” “should,” “could,” “may” and similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to projections for our future financial performance, anticipated growth trends in the Company’s business and other characterizations of future events or circumstances are forward-looking statements, including statements regarding the Company’s ability to continue as a going concern and the Company’s ability to maintain the listing of its shares on the NYSE American. Readers also should carefully review the risk factors included in other documents the Company files from time to time with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, or, in the case of other documents referred to herein, the dates of those documents. The Company undertakes no obligation to publicly revise or update these forward-looking statements to reflect events or circumstances that arise after the date hereof, except as may be required under applicable law. The Company’s actual results may differ from the anticipated results or other expectations expressed in these forward-looking statements.

 

Contacts

 

Eric Skolnik
Chief Financial Officer
eskolnik@blondertongue.com
(732) 679-4000

 

Ted Grauch

Chief Executive Officer
tgrauch@blondertongue.com
(732) 679-4000

 

Press Contacts:

Bob Gold

Bob Gold & Associates

bob@bobgoldpr.com

(office) 310-320-2010

 

More…

 

 

© Blonder Tongue Laboratories, Inc. | One Jake Brown Road, Old Bridge, NJ 08857 | (800) 523-6049 | Fax: (732) 679-4353 | www.blondertongue.com

 

 3 

 

 

 

 

Blonder Tongue Laboratories, Inc.

Condensed Consolidated Summary of Operating Results

(unaudited, in thousands, except per share data)

  

   Three months ended   Six months ended 
   June 30,   June 30, 
   2021   2020   2021   2020 
                 
Net sales  $4,338   $3,831   $7,589   $7,881 
Gross profit   1,605    1,235    2,990    1,788 
Loss from operations   (617)   (1,108)   (1,480)   (3,127)
Net income (loss)  $1,626   $(1,194)  $1,212   $(3,274)
Basic net income (loss) per share  $0.14   $(0.12)  $0.10   $(0.34)
Diluted net income (loss) per share  $0.11   $(0.12)  $0.08   $(0.34)
Basic weighted average shares outstanding   11,984    9,766    11,818    9,766 
Diluted weighted average shares outstanding   15,254    9,766    15,186    9,766 

 

Blonder Tongue Laboratories, Inc

Condensed Consolidated Summary Balance Sheets

(in thousands)

 

  

June 30,

2021

  

December 31,

2020

 
   (unaudited)     
Current assets  $7,113   $6,104 
Property, plant and equipment, net   648    429 
Total assets   11,908    11,130 
Current liabilities   5,515    5,534 
Long-term liabilities   2,903    4,359 
Stockholders’ equity   3,490    1,237 
           
Total liabilities and stockholders’ equity  $11,908   $11,130 

 

More…

 

 

4

 


The following information was filed by Blonder Tongue Laboratories Inc (BDR) on Thursday, August 12, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Blonder Tongue Laboratories Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Blonder Tongue Laboratories Inc.

Continue

Assess how Blonder Tongue Laboratories Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Blonder Tongue Laboratories Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Legal
Revenue
Financial
Other
Filter Subcategory:
All
Product
Debt
Expense
Income
Other
Inside Blonder Tongue Laboratories Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parentheticals)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Stockholders??? Equity (Unaudited)
Accounting Policies, By Policy (Policies)
Commitments And Contingencies
Commitments And Contingencies (Details)
Commitments And Contingencies (Details) - Schedule Of Maturities Of The Lease Liabilities
Commitments And Contingencies (Tables)
Company And Basis Of Consolidation
Concentration Of Credit Risk
Concentration Of Credit Risk (Details) - Schedule Of Credit Risk With Respect To Customers As Percentage Of Accounts Receivable
Concentration Of Credit Risk (Details) - Schedule Of Credit Risk With Respect To Customers As Percentage Of Sales
Concentration Of Credit Risk (Details) - Schedule Of Credit Risk With Respect To Vendors As Percentage Of Accounts Payable
Concentration Of Credit Risk (Details) - Schedule Of Credit Risk With Respect To Vendors As Percentage Of Purchases
Concentration Of Credit Risk (Tables)
Debt
Debt (Details)
Inventories
Inventories (Details)
Inventories (Details) - Schedule Of Inventories Net Of Reserves
Inventories (Tables)
Other Income
Other Income (Details)
Related Party Transactions
Related Party Transactions (Details)
Revenue Recognition
Revenue Recognition (Details) - Schedule Of Disaggregation Revenues
Revenue Recognition (Tables)
Subordinated Convertible Debt With Related Parties
Subordinated Convertible Debt With Related Parties (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Details) - Schedule Of Basic And Diluted Net Income
Summary Of Significant Accounting Policies (Details) - Schedule Of Diluted Potential Common Shares Due To Their Antidilutive Effect
Summary Of Significant Accounting Policies (Tables)

Material Contracts, Statements, Certifications & more

Blonder Tongue Laboratories Inc provided additional information to their SEC Filing as exhibits

Ticker: BDR
CIK: 1000683
Form Type: 10-Q Quarterly Report
Accession Number: 0001213900-21-041828
Submitted to the SEC: Thu Aug 12 2021 9:29:28 AM EST
Accepted by the SEC: Thu Aug 12 2021
Period: Wednesday, June 30, 2021
Industry: Radio And Tv Broadcasting And Communications Equipment

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/bdr/0001213900-21-041828.htm